These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38143496)

  • 1. A synthetic notch (synNotch) system linking intratumoral immune-cancer cell communication to a synthetic blood biomarker assay.
    Fu Y; Wang T; Ronald JA
    Front Pharmacol; 2023; 14():1304194. PubMed ID: 38143496
    [No Abstract]   [Full Text] [Related]  

  • 2. Visualizing cell-cell communication using synthetic notch activated MRI.
    Wang T; Chen Y; Nystrom NN; Liu S; Fu Y; Martinez FM; Scholl TJ; Ronald JA
    Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2216901120. PubMed ID: 36893267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models.
    Hyrenius-Wittsten A; Su Y; Park M; Garcia JM; Alavi J; Perry N; Montgomery G; Liu B; Roybal KT
    Sci Transl Med; 2021 Apr; 13(591):. PubMed ID: 33910981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target-Dependent Expression of IL12 by synNotch Receptor-Engineered NK92 Cells Increases the Antitumor Activities of CAR-T Cells.
    Luo H; Wu X; Sun R; Su J; Wang Y; Dong Y; Shi B; Sun Y; Jiang H; Li Z
    Front Oncol; 2019; 9():1448. PubMed ID: 31921693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering a Programmed Death-Ligand 1-Targeting Monobody Via Directed Evolution for SynNotch-Gated Cell Therapy.
    Zhu L; Man CW; Harrison RES; Wu Z; Limsakul P; Peng Q; Hashimoto M; Mamaril AP; Xu H; Liu L; Wang Y
    ACS Nano; 2024 Mar; 18(11):8531-8545. PubMed ID: 38456901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma.
    Schomer NT; Jiang ZK; Lloyd MI; Klingemann H; Boissel L
    Cytotherapy; 2022 Aug; 24(8):827-834. PubMed ID: 35400595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visualizing CAR-T cell Immunotherapy Using 3 Tesla Fluorine-19 MRI.
    Dubois VP; Sehl OC; Foster PJ; Ronald JA
    Mol Imaging Biol; 2022 Apr; 24(2):298-308. PubMed ID: 34786668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma.
    Noh KE; Lee JH; Choi SY; Jung NC; Nam JH; Oh JS; Song JY; Seo HG; Wang Y; Lee HS; Lim DS
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering Axl specific CAR and SynNotch receptor for cancer therapy.
    Cho JH; Okuma A; Al-Rubaye D; Intisar E; Junghans RP; Wong WW
    Sci Rep; 2018 Mar; 8(1):3846. PubMed ID: 29497107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmenting the Antitumor Efficacy of Natural Killer Cells via SynNotch Receptor Engineering for Targeted IL-12 Secretion.
    Ahmadnia A; Mohammadi S; Yamchi A; Kalani MR; Farazmandfar T; Khosravi A; Memarian A
    Curr Issues Mol Biol; 2024 Mar; 46(4):2931-2945. PubMed ID: 38666913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Comparison between Endogenous and Synthetic Notch Systems.
    Khamaisi B; Luca VC; Blacklow SC; Sprinzak D
    ACS Synth Biol; 2022 Oct; 11(10):3343-3353. PubMed ID: 36107643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.
    Roselli E; Boucher JC; Li G; Kotani H; Spitler K; Reid K; Cervantes EV; Bulliard Y; Tu N; Lee SB; Yu B; Locke FL; Davila ML
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients.
    Taştan C; Kançağı DD; Turan RD; Yurtsever B; Çakırsoy D; Abanuz S; Yılancı M; Seyis U; Özer S; Mert S; Kayhan CK; Tokat F; Açıkel Elmas M; Birdoğan S; Arbak S; Yalçın K; Sezgin A; Kızılkılıç E; Hemşinlioğlu C; İnce Ü; Ratip S; Ovalı E
    Turk J Haematol; 2020 Nov; 37(4):234-247. PubMed ID: 32755128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia.
    Rozenbaum M; Meir A; Aharony Y; Itzhaki O; Schachter J; Bank I; Jacoby E; Besser MJ
    Front Immunol; 2020; 11():1347. PubMed ID: 32714329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCL10 encoding synNotch T cells enhance anti-tumor immune responses without systemic side effect.
    Xia M; Chen J; Meng G; Shen H; Dong J
    Biochem Biophys Res Commun; 2021 Jan; 534():765-772. PubMed ID: 33213838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the efficacy of second and third generation lentiviral vector transduced CAR CD19 T cells for use in the treatment of acute lymphoblastic leukemia both in vitro and in vivo models.
    Sawaisorn P; Atjanasuppat K; Uaesoontrachoon K; Rattananon P; Treesuppharat W; Hongeng S; Anurathapan U
    PLoS One; 2023; 18(2):e0281735. PubMed ID: 36780428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FLAG-tagged CD19-specific CAR-T cells eliminate CD19-bearing solid tumor cells
    Berahovich R; Xu S; Zhou H; Harto H; Xu Q; Garcia A; Liu F; Golubovskaya VM; Wu L
    Front Biosci (Landmark Ed); 2017 Jun; 22(10):1644-1654. PubMed ID: 28410137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line.
    Kang CH; Kim Y; Lee HK; Lee SM; Jeong HG; Choi SU; Park CH
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A programmable arthritis-specific receptor for guided articular cartilage regenerative medicine.
    Walton BL; Shattuck-Brandt R; Hamann CA; Tung VW; Colazo JM; Brand DD; Hasty KA; Duvall CL; Brunger JM
    bioRxiv; 2024 Feb; ():. PubMed ID: 38352576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.